CERS News and Press, Cerus Corporation From 02/28/23

Cerus press release ( NASDAQ: CERS ): Q4 GAAP EPS of -$0.08 misses by $0.02 . Product revenue of $44.03M (+10.4% Y/Y) beats by $0.56M . Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million For further details see: Cerus GAAP...

Strong Revenue Growth Driven by Sales in North America Product Revenue of $44.0 Million Grew 10% YoY in the Fourth Quarter Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million Cerus Corporation (Nasdaq: CERS) today announced financial results for...

Summary Cathie Wood and her ARK Investment Management have just turned their backs on their worst year of performance since the inception of the investing firm. The market continued to systematically dissect any leftover enthusiasm in the growth and technology space, significantly hurti...

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which manag...

Summary Cerus pushed below its longer-term support level after issuing FY23E guidance in January. The market priced in its fair value of the stock swiftly and hasn't added a reasonable bid since. Market-generated data indicates further sideways congestion is a high probability, and ...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Growth stocks are bouncing back in 2023, and that finds Cathie Wood's growth-investing style back in fashion. The CEO, founder, and primary analyst at Ark Invest is seeing her firm's exchange-traded funds (ETFs) start rolling again this year after back-to-back years of devastating declines. A...

Cerus Corporation ( NASDAQ: CERS ) dropped ~19% in the morning hours Monday after the maker of INTERCEPT Blood System set its forecast for full-year 2023 product revenue at $165M – $170M. Wall Street forecasts the company to report $193.3 of total revenue in 2023. Cerus ( ...

Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth of 10% and 24%, respectively Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and pro...

Cerus Corporation (CERS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 P.M. ET Company Participants Jessica Hanover - Vice President, Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kev...